NANOFÁRMACOS

Volver

Resultados 131 resultados LastUpdate Última actualización 26/05/2017 [14:49:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 6 nextPage   Mostrar por página


IONIC AQUEOUS FLUID COMPOSITION CONTAINING OXYGEN MICROBUBBLES

NºPublicación: EP3170401A1 24/05/2017

Solicitante:
REVALESIO CORP [US]

Resumen de: EP3170401A1

An oxygenated ionic aqueous fluid composition comprising oxygen-containing microbubbles predominantly having an average diameter of less than 100 nanometers. The oxygen is present in an amount of at least 15 ppm at atmospheric pressure.The fluids can be suitable for food and pharmaceutical applications, as well as for bioreactor systems.



traducir


 

TREATMENT OF CANCER WITH A COMBINATION OF RADIATION, CERIUM OXIDE NANOPARTICLES, AND A CHEMOTHERAPEUTIC AGENT

NºPublicación: EP3169312A1 24/05/2017

Solicitante:
BIOCURITY HOLDINGS INC [US]

Resumen de: WO2016011328A1

The present invention is directed to methods for the treatment of cancer with a combination of radiation, cerium oxide nanoparticles and at least one chemotherapeutic agent. Cerium oxide nanoparticles (CONPs) are nanometer-sized crystals of cerium oxide, typically ranging between about one nanometer to about 20 nanometers in longest dimension. The present methods use cerium oxide nanoparticles to enhance radiation-induced and chemotherapy-induced cancer cell death and also reduce the toxicity associated with radiation therapy and chemotherapy



traducir


 

COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC AND IMAGING AGENTS TO THE SINUSES AND MIDDLE EAR

NºPublicación: HK1220888A1 19/05/2017

Solicitante:
GEORGIA STATE UNIV RES FOUND INC [US]

Resumen de: WO2014145308A1

The present invention features compositions and methods for targeted delivery of a therapeutic or imaging agent to a site accessible through the nose or mouth that may be difficult to effectively and efficiently treat otherwise (e.g., the middle ear, sinuses, or lung). The therapeutic or imaging agent is deposited onto a magnetic nanoparticle that is drawn through a passage or tissue that leads away from the nose or mouth by a magnetic field applied over the targeted site (e.g., by magnets within the ear canal or surrounding the ear).



traducir


 

METHODS OF DETERMINING FEATURES OF POLYMERIC NANOPARTICLES THAT INCLUDE A THERAPEUTIC AGENT

NºPublicación: WO2017081606A1 18/05/2017

Solicitante:
PFIZER [US]

Resumen de: WO2017081606A1

The present disclosure generally relates to methods of determining the structural features corresponding to the release rate of a therapeutic agent in a therapeutic nanoparticle. Such nanoparticles may include the therapeutic agent. In particular, the application discloses a method of determining the structural features corresponding to the release rate of a therapeutic agent in a therapeutic nanoparticle that includes the therapeutic agent and a hydrophobic counterion, comprising: obtaining a Raman spectra of the nanoparticle; comparing the Raman spectra of the nanoparticle to a Raman spectra of at least one of the therapeutic agent alone, the hydrophobic counterion alone, a nanoparticle that does not include the therapeutic agent, and a salt formed from the therapeutic agent and the hydrophobic counterion to determine whether the therapeutic agent and the hydrophobic counterion in therapeutic nanoparticle occur as a salt.



traducir


 

Chimeric proteins

NºPublicación: AU2015330971A1 18/05/2017

Solicitante:
LIPOTEK PTY LTD
THE AUSTRALIAN NAT UNIV

Resumen de: AU2015330971A1

The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticle carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. An embodiment of the chimeric protein comprises of a TLR5 agonist such as a flagellin, and a gpl20-derived peptide. The invention is also directed to methods of internalising an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins.



traducir


 

Pharmaceutical preparation of camptothecin-containing polymer derivative

NºPublicación: AU2015369185A1 18/05/2017

Solicitante:
NIPPON KAYAKU KK

Resumen de: AU2015369185A1

The present invention addresses the problem of providing a pharmaceutical preparation composition which is a pharmaceutical preparation containing a polymerized camptothecin derivative produced by bonding a camptothecin derivative capable of associating in an aqueous solution thereof to form nano particle to a polymer carrier, and which has improved pharmaceutical stability. Particularly, the present invention addresses the problem of providing a pharmaceutical preparation capable of maintaining the nano particle-forming property thereof, which is an important factor, and having excellent storage stability. A pharmaceutical preparation which contains a block copolymer composed of a polyethylene glycol segment and a polyglutamic acid segment linked to each other, wherein the polyglutamic acid segment contains a glutamic acid unit having a camptothecin derivative bonded thereto. In an aqueous solution of the pharmaceutical preparation, associations can be formed. When the pharmaceutical preparation is prepared into an aqueous solution containing the camptothecin derivative at a concentration of 1 mg/mL, the aqueous solution has a pH value of 2.4 to 7.0. In the pharmaceutical preparation, the rate of change in the ability of forming the associations after the pharmaceutical preparation is stored at 40°C for 1 week under light-blocked conditions is 50% or less.



traducir


 

Compositions and methods for targeted thermomodulation

NºPublicación: AU2017202704A1 18/05/2017

Solicitante:
SIENNA BIOPHARMACEUTICALS INC

Resumen de: AU2017202704A1

COMPOSITIONS AND METHODS FOR TARGETED THERMOMODULATION Provided are nanoparticles and formulations which are useful for cosmetic, diagnostic and therapeutic applications to mammals such as humans.



traducir


 

NANOPARTICULATE FORMULATION COMPRISING A mPGES-1 INHIBITOR

NºPublicación: US2017135991A1 18/05/2017

Solicitante:
GLENMARK PHARMACEUTICALS SA [CH]

Resumen de: US2017135991A1

The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 (“mPGES-1”) inhibitor. Particularly, the present invention relates to a nanoparticulate formulation comprising an mPGES-1 inhibitor and one or more surface stabilizers; a process for preparing such formulation; and its use in treating pain and inflammation in a subject.



traducir


 

COMPOSITIONS AND METHODS FOR MODULATING MYELOID DERIVED SUPPRESSOR CELLS

NºPublicación: US2017137812A1 18/05/2017

Solicitante:
MOHAPATRA SHYAM S [US]
BHARADWAJ SRINIVAS NAGARAJ [US]
MOHAPATRA SUBHRA [US]
UNIV SOUTH FLORIDA [US]

Resumen de: US2017137812A1

Provided are methods of treating an inflammatory disease in a subject in need thereof by administering an amount of microRNA 142, an amount of microRNA 223 or an amount of microRNA 142 and an amount of micro RNA 223 to the subject in need thereof.



traducir


 

Insulin-Containing Prolonged-Action Preparation

NºPublicación: US2017136096A1 18/05/2017

Solicitante:
OBSCHESTVO S OGRANCHENNOJ OTVETCTVENNOSTU BIOSABTEK [RU]

Resumen de: US2017136096A1

The invention relates to the field of biotechnology and medicine, and specifically to insulin-containing injectable formulations used, in particular, for treating diabetes mellitus. The present formulation comprises insulin and a pharmacologically acceptable polymer having a hydrodynamic diameter of more than 4.5+/−0.5 nanometers. As said polymer, at least one polymer having a molecular weight of 20-70 kDa may be optimally used, and is selected from a group including: dextran, polyethylene glycol and albumin. As regards insulin formulations used, it is possible to use human recombinant insulin and genetically engineered analogs thereof used in the commercial formulations. Experiments have shown that using the aforementioned polymers provides insulin formulations with a prolonged effect without the use of chemical or genetic methods of modifying insulin molecules. The method of long acting formulations preparing is not dependent on biotherapeutics and thus it can be used over range of therapeutic proteins.



traducir


 

Stabilised Formulations of RNA

NºPublicación: US2017136129A1 18/05/2017

Solicitante:
BIONTECH AG [DE]

Resumen de: US2017136129A1

The present invention relates to stable low-salt aqueous formulations of particles comprising a polycation, preferably protamine, and RNA, which formulations are preferably isotonic, to pharmaceutical compositions or kits comprising such formulations and to their use in medicine. It further relates to methods for preparing the formulations of the invention and to methods for physically stabilizing particles comprising a polycation, preferably protamine, and RNA.



traducir


 

NOVEL DIESTER AND TRIESTER BASED LOW MOLECULAR WEIGHT, BIODEGRADEABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY

NºPublicación: US2017135962A1 18/05/2017

Solicitante:
SIRNA THERAPEUTICS INC [US]

Resumen de: US2017135962A1

The instant invention provides for novel cationic lipids of Formula A that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.



traducir


 

STANNOUS DOPED MICRO AND NANO PARTICLES FOR AUGMENTED RADIOFREQUENCY ABLATION

NºPublicación: US2017136123A1 18/05/2017

Solicitante:
AMRITA VISHWA VIDYAPEETHAM [IN]

Resumen de: US2017136123A1

A composition for facilitating localized delivery of energy and of therapeutic agents to a lesion in tissue is disclosed comprising nanoparticles of a polysaccharide, gelatin or a polymer, wherein the nanoparticles are complexed with tin ions. The composition may comprise one or more therapeutic agents. The composition may be configured to improve the thermal effect of RF energy on a lesion and or to release the therapeutic agents to the lesion when RF energy is applied.



traducir


 

NUCLEIC ACID FUNTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS

NºPublicación: US2017137809A1 18/05/2017

Solicitante:
UNIV NORTHWESTERN [US]

Resumen de: US2017137809A1

Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.



traducir


 

METHYLPREDNISOLONE-IMMUNE NANO-LIPOSOME WITH HUMAN LUNG TISSUE ACTIVE TARGETING PERFORMANCE AND PREPARATION METHOD THEREFOR

NºPublicación: WO2017080002A1 18/05/2017

Solicitante:
SHANGHAI PULMONARY HOSPITAL [CN]

Resumen de: WO2017080002A1

A methylprednisolone-immune nano-liposome with human lung tissue active targeting performance. A nano-liposome carrying a therapeutic agent is covalently coupled to a human lung surfactant protein A nanobody. The therapeutic agent is methylprednisolone sodium succinate. The nano-liposome consists of phospholipid, cholesterol, and a long-circulating material. The molar ratio of the methylprednisolone sodium succinate to the phospholipid in the nano-liposome is 0.30-0.45.



traducir


 

TOPICAL FORMULATIONS AND USES THEREOF

NºPublicación: WO2017083167A1 18/05/2017

Solicitante:
OCULAR TECH SARL [CH]
WEISS SIDNEY L [US]

Resumen de: WO2017083167A1

Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.



traducir


 

NANO- AND MICRO-SIZED PARTICLES OF 20-CAMPTOTHECIN OR DERIVATIVE THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND TREATMENT OF CANCERS THEREWITH

NºPublicación: WO2017083151A1 18/05/2017

Solicitante:
CAO PHARMACEUTICALS INC [US]

Resumen de: WO2017083151A1

A pharmaceutical composition is provided having particles of a physical mixture that contain at least one 20-camptothecin or a derivative thereof, at least one surfactant, at least one stabilizer, and at least one diluent. The particles have a mean particle size of less than about 2500 nm. The pharmaceutical composition can be nano- or micro-sized particles containing the 20-camptothecin esters or derivatives thereof as part of a physical mixture, which can provide the active compound in a water-soluble/dispersible, bioavailable form. The particles can be used as an oral pharmaceutical composition which comprises the nano- or micro-sized form of 20-camptothecin esters or derivatives, such as in an oral suspension (e.g., an aqueous suspension), or capsules, or caplets. The pharmaceutical composition can be used in the treatment of a cancer or malignant tumor in a patient by oral administration thereof in a therapeutically effective amount.



traducir


 

APPARATUS FOR MANUFACTURING NANOCOMPOSITE AND SELF-ASSEMBLY MANUFACTURING METHOD

NºPublicación: WO2017082610A1 18/05/2017

Solicitante:
RES COOP FOUND OF YEUNGNAM UNIV [KR]

Resumen de: WO2017082610A1

The present invention relates to a self-assembly manufacturing method of a nanocomposite and, more particularly, to a self-assembly manufacturing method of a nanocomposite comprising the steps of: spraying a drug-containing solution onto metal aerosol nanoparticles to form a drug layer on the metal aerosol nanoparticles; and spraying a polymer-containing solution onto the metal aerosol nanoparticles formed with the drug layer to form a polymer layer on the drug layer. Since the method for manufacturing a nanocomposite through a self-assembly process does not involve a liquid phase chemical process when manufacturing metal aerosol nanoparticles, the process is simple, the process can be performed even at low temperatures so that the deformation of an organic substance or a drug can be suppressed, and the release rate of the drug through the kinds of metal of the metal aerosol nanoparticles, modification, etc. can be easily controlled.



traducir


 

TOPICAL FORMULATIONS AND USES THEREOF

NºPublicación: WO2017083410A1 18/05/2017

Solicitante:
OCULAR TECH SARL [CH]
WEISS SIDNEY L [US]

Resumen de: WO2017083410A1

Provided herein include formulations of defined active agents for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also included are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.



traducir


 

SYNTHETIC SOMATOSTATIN RECEPTOR LIGANDS

NºPublicación: EP3166967A1 17/05/2017

Solicitante:
TEL HASHOMER MEDICAL RES INFRASTRUCTURE AND SERVICES LTD [IL]
RAMOT AT TEL-AVIV UNIV LTD [IL]

Resumen de: WO2016038565A1

Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.



traducir


 

AMPHIPHILIC PEPTIDE NANOPARTICLES FOR USE AS HYDROPHOBIC DRUG CARRIERS AND ANTIBACTERIAL AGENTS

NºPublicación: EP3166643A1 17/05/2017

Solicitante:
UNIV NORTHEASTERN [US]

Resumen de: WO2016007664A1

Nanoparticulate carrier formulations are useful to solubilize, deliver, and target hydrophobic drugs for treating diseases including cancer and bacterial infections. The formulations contain amphiphilic peptides having a hydrophobic portion and a positively charged hydrophilic portion. The peptides self-associate at nonacidic pH to form micelles with a spherical nanoparticle morphology. The hydrophobic core of the nanoparticles encapsulates hydrophobic drugs, including antitumor agents, increasing their solubility in water and allowing them to be targeted, for example, to cancer cells. The positively charged surface of the nanoparticles, together with an optional targeting moiety such as an RGD peptide, allows the nanoparticles to bind selectively to mammalian cells and bacterial cells, including cancer cells that overexpress integrin receptors. The pH-dependence of the nanoparticle association/dissociation can be employed to conveniently load the nanoparticles with hydrophobic drug using a controlled pH shift, and unload them in acidic intracellular compartments. The ability of the carrier formulations to solubilize and target hydrophobic drugs gives rise to strategies for the selective inhibition or killing of cancer cells, such as the killing of osteosarcoma cells using the drug curcumin. The amphiphilic peptides and nanoparticles derived therefrom also give rise to additional compositions and methods that have useful bacteriocidal features as well as the ability to promot



traducir


 

COMPOSITIONS AND DELIVERY METHODS FOR TREATING DENTAL INFECTIONS, INFLAMMATION, SENSITIVITY, AND FOR USE IN DENTAL RESTORATIONS

NºPublicación: EP3166648A2 17/05/2017

Solicitante:
UNIV MARYLAND [US]
UNIV OF MARYLAND [US]

Resumen de: WO2016007629A2

The present invention provides a method of treating a condition affecting a tooth or periodontium in a subject, comprising administering to the subject's tooth or periodontium a composition comprising biocompatible magnetic, magnetizable, or magnetically responsive agents; and applying an external magnetic field, wherein the magnetic, magnetizable, or magnetically responsive agents migrate to a desired location in response to the externally applied magnetic field, thereby treating a condition affecting the tooth or periodontium in the subject.



traducir


 

REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS

NºPublicación: EP3167875A1 17/05/2017

Solicitante:
ALKERMES PHARMA IRELAND LTD [IE]

Resumen de: EP3167875A1

This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000nm.



traducir


 

A COMPOSITION FOR USE IN A METHOD FOR PREVENTION OR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS

NºPublicación: WO2017077520A1 11/05/2017

Solicitante:
INEB - INST NAC DE ENGENHARIA BIOM\u00C9DICA [PT]

Resumen de: WO2017077520A1

The present disclosure provides a new microbicide pharmaceutical composition for topical pre-exposure prophylaxis or topical post-exposure prophylaxis. The present disclosure relates to the incorporation of nanoparticles loaded with different antiretroviral compounds in soft and flexible vaginal films. Antiretroviral compounds may be present in films either as single agent or in combination with nanoparticles. Antiretroviral-loaded nanoparticles-in-vaginal films are to be administered in the vagina around the time of sexual intercourse in order to prevent the sexual transmission of HIV.



traducir


 

COMPOSITION COMPRISING A BIOCOMPATIBLE AND BIODEGRADABLE POLYMER, NANOCARRIES AND A DRUG AND METHODS OF MAKING AND USING THE SAME

Nº publicación: WO2017077066A1 11/05/2017

Solicitante:
FRAUNHOFER-GESELLSCHAFT ZUR F\u00D6RDERUNG DER ANGEWANDTEN FORSCHUNG E V [DE]

Resumen de: WO2017077066A1

The present invention pertains to a composition comprising at least one biocompatible and biodegradable polymer, said polymer further comprising nanocarriers wherein said nanocarriers comprise a drug. Moreover, also encompassed by the invention is the use of said composition in the treatment of a disease and a method for manufacturing said composition.


traducir



 

Página1 de 6 nextPage Mostrar por página

Volver